* AC Immune SA ACIU.OQ ACIU.O is expected to show a rise
in
quarterly revenue when it reports results on March 11
(estimated) for the period ending December 31 2023
* The Lausanne Vaud-based company is expected to report a
1,003,233.0% increase in revenue to CHF10.033 million from CHF1
thousand a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for AC Immune SA is for a
loss
of 11 rappen per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AC Immune
SA is
$9.00, above its last closing price of $3.88.
Previous quarterly performance (using preferred earnings measure
in Swiss francs).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.07 0.03 -0.18 Missed -801.2
Jun. 30 2023 -0.19 -0.20 -0.20 Met -1.4
Mar. 31 2023 -0.23 -0.23 -0.21 Beat 8.5
Dec. 31 2022 -0.25 -0.23 Beat 8.7
Sep. -0.27 -0.24 -0.16 Beat 33.8
30 2022
Jun. 30 2022 -0.25 -0.23 -0.23 Met 1
Mar. 31 2022 -0.22 -0.22 -0.23 Missed -3.8
Dec. 31 2021 0.82 0.10 -0.28 Missed -373.1
This summary was machine generated March 8 at 13:16 GMT. All
figures in Swiss francs unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)